Status: Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Madrigal Pharmaceuticals, Inc.Updated: Jun 16, 2026Locations: 17
Eligibility criteria
Cohort 1: Liver transplant for MASH cirrhosis with recurrent hepatic steatosis ≥... [+7]
Participation in another interventional clinical trial with investigational drug... [+20]